Shanghai venture will bring advanced cell therapies to China

Written by Freya Leask

Learn more about the Advanced Cell Therapy Shanghai Summit (29—31 October 2018; Shanghai, China).

The Advanced Cell Therapy Shanghai Summit (ACTSS)(29—31 October 2018) will take place at the Kerry Hotel Pudong (Shanghai, China). ACTSS is the only event in China to offer global coverage of ATMPs from research and development to manufacturing and market access. The event is poised to capitalize on improved access to infrastructure and investment in advanced therapies, creating major opportunities in China.

The joint venture between ACTSS and Phacilitate (London, UK) will build on the success of the first edition of ACTSS in 2017. The market approval of KYMRIAH® and YESCARTA® created a great deal of buzz last year and over the last 12 months, CAR-T has become increasingly relevant as new technologies, clinical developments and regulatory advances emerge. Billion dollar deals were closed on CAR-T assets and millions have been invested in start-ups focused on advanced therapy development.

ACTSS 2018 will explore developments in global regulations in cell and gene therapy, discuss critical insights into cGMP manufacturing best practices and explore next generation technologies and their potential to shape the autologous CAR-T landscape in the next 3-5 years.

ACTSS topics will include:

  • Next generation advanced therapies
  • Switchable and transient CAR-T
  • Global supply chains for advanced therapies
  • Manufacturing best practices

More than 70 speakers are confirmed on the agenda, including visionaries like Stephan A. Grupp (Chief Cellular Therapy & Transplant Section Children’s Hospital of Philadelphia; PA, USA), John Rasko (President, ISCT), Bruce L. Levine (Barbara and Edward Netter Professor in Cancer Gene Therapy Pennsylvania Perelman School of Medicine; PA, USA),Xu Fang (Sanpower Group; Nanjing, China) and many more. 

Watch an interview with John Rasko from ISCT 2017>>

“We are very pleased to build on the event we created in 2017,” said Cindy Ru, Managing Director of CRC and Chair of Advisory Board of ACTSS. “With a rapidly growing scientific infrastructure in China, the global community needs a global gathering like ACTSS to learn about the emergence of incredible manufacturing capability, investment and high quality research. 

Watch an interview with Bruce Levine from ISCT 2018>>

“Our event creates opportunities for Chinese investors to meet Western companies and for Western companies to learn more about working in China. We are proud to partner with Phacilitate, as their reputation of creating unique conference experiences is well-known globally.”

To review a full agenda, visit